← All trials
NCT05226390
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2022
- Primary completion
- Feb 28, 2023
- Completion date
- Oct 31, 2023
- First posted
- Feb 7, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gottfried Wilhelm Leibniz Universität HannoverLead sponsor
- University of HamburgCollaborator
- German Center for Infection ResearchCollaborator
- Hannover Medical SchoolOverall official - principal investigator
- Hannover Medical SchoolStudy chair
- IDT BiologikaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.